Work

Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.1094

Authors: Zachary William Neil Veitch, David W. Cescon, Sawako Elston, Scott Lien, Cindy Yang, Ben X Wang, Hal K. Berman, Marcus O. Butler, Eitan Amir, Christine Elser, Sevan Hakgor, Amanda Giesler, Trevor John Pugh, Pamela S Ohashi, Lillian L. Siu, Philippe L. Bedard

Institutions: Princess Margaret Cancer Centre, University Health Network, Mount Sinai Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2806941772

Cites:

Cited by: 4

Related to: 10